[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2016091888A3 - Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics - Google Patents

Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics Download PDF

Info

Publication number
WO2016091888A3
WO2016091888A3 PCT/EP2015/078999 EP2015078999W WO2016091888A3 WO 2016091888 A3 WO2016091888 A3 WO 2016091888A3 EP 2015078999 W EP2015078999 W EP 2015078999W WO 2016091888 A3 WO2016091888 A3 WO 2016091888A3
Authority
WO
WIPO (PCT)
Prior art keywords
individual
pdac
transcriptomics
phenotyping
kits
Prior art date
Application number
PCT/EP2015/078999
Other languages
French (fr)
Other versions
WO2016091888A2 (en
Inventor
Nelson Dusetti
Juan Lucio Iovanna
Ezequiel CALVO
Odile GAYET
Céline LONCLE
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Centre Hospitalier Universitaire De Quebec
Centre National De La Recherche Scientifique (Cnrs)
Université D'aix-Marseille
Institut Jean Paoli & Irene Calmettes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre Hospitalier Universitaire De Quebec, Centre National De La Recherche Scientifique (Cnrs), Université D'aix-Marseille, Institut Jean Paoli & Irene Calmettes filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Publication of WO2016091888A2 publication Critical patent/WO2016091888A2/en
Publication of WO2016091888A3 publication Critical patent/WO2016091888A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

An in vitro or ex vivo method for determining the prognosis of an individual having Pancreatic Adenocarcinoma (PDAC), or the efficiency of a compound for treating PDAC in said individual, comprising the steps of: a1) measuring, in a biological sample from said individual, the expression level of one or more PDAC marker genes selected from a first group of PDAC marker genes consisting of: CACNA1D; CFTR; MUC3A; NPC1L1; ONECUT2; PROM1; SLC6A20; SLC40A1; HSD17B3; YAE1D1; MIPOL1; ALOX12P2; SRD5A3; SNTB1; KCNK1; HIST1H3E; SEC16B; PCDH7; KCNMB4; MIR4500; ARL4D; MIR1206; SRPX2; WFS1; DDX26B; WDR78; AGMO; and EDN1; a2) measuring, in a biological sample from said individual, the expression level of one or more gene selected from a second group consisting of: DUSP5; FJX1; ITGA10; MT1A; VIM; CCNE1; THBS3; TRAF5; LTA4H; SAMHD1; SNORD14E; PRKX; PKIA; RHOBTB1; AK128855; CMBL; SMAD4; ARRB2; and HIST2H3D; b) determining the prognosis of said individual, or the efficiency of said compound from the measurement performed in steps a1) and a2).
PCT/EP2015/078999 2014-12-08 2015-12-08 Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics WO2016091888A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306967 2014-12-08
EP14306967.2 2014-12-08

Publications (2)

Publication Number Publication Date
WO2016091888A2 WO2016091888A2 (en) 2016-06-16
WO2016091888A3 true WO2016091888A3 (en) 2016-08-11

Family

ID=52282581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/078999 WO2016091888A2 (en) 2014-12-08 2015-12-08 Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics

Country Status (1)

Country Link
WO (1) WO2016091888A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147593A2 (en) * 2016-02-26 2017-08-31 University Of Hawaii Long intergenic non-coding rna as pan-cancer biomarker
WO2018095933A1 (en) 2016-11-22 2018-05-31 Université D'aix-Marseille (Amu) Method of prognosticating, or for determining the efficiency of a compound for treating cancer
US20190127795A1 (en) * 2017-04-13 2019-05-02 Tiffany Wu Method for prognosing and reducing cardiovascular disease in patients with kidney diseases
CN113189344B (en) * 2018-07-09 2022-08-19 南京艾蓝生物科技有限公司 Application of PDLIM4 as gastric cancer marker
CN109321657B (en) * 2018-10-30 2021-07-02 徐州医科大学 Glioma prognosis marker and application thereof
CN110632317A (en) * 2019-10-28 2019-12-31 四川大学华西医院 Application of SAMHD autoantibody detection reagent in preparation of lung cancer screening kit
KR20230044315A (en) * 2020-08-07 2023-04-03 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Methods and compositions for evaluating and treating pancreatic cancer
WO2022207566A1 (en) * 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
CN115212308B (en) * 2021-04-15 2023-10-20 中国医学科学院基础医学研究所 Application of GASDERMIN E pathway targeting agent in treating pancreatic cancer
EP4098754A1 (en) * 2021-06-04 2022-12-07 Institut National De La Sante Et De La Recherche Medicale - Inserm Rna signature of pdac sensitivities to anticancer treatments
CN115992229B (en) * 2022-07-22 2023-07-07 中南大学湘雅三医院 lncRNA marker and model for pancreatic cancer prognosis risk assessment and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056963A1 (en) * 2009-11-04 2011-05-12 The University Of North Carolina At Chapel Hill Methods and compositions for predicting survival in subjects with cancer
EP2716767A1 (en) * 2012-10-04 2014-04-09 Skuldtech Method for determining the prognosis of pancreatic cancer
WO2014186773A1 (en) * 2013-05-17 2014-11-20 National Health Research Institutes Methods of prognostically classifying and treating glandular cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056963A1 (en) * 2009-11-04 2011-05-12 The University Of North Carolina At Chapel Hill Methods and compositions for predicting survival in subjects with cancer
EP2716767A1 (en) * 2012-10-04 2014-04-09 Skuldtech Method for determining the prognosis of pancreatic cancer
WO2014186773A1 (en) * 2013-05-17 2014-11-20 National Health Research Institutes Methods of prognostically classifying and treating glandular cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARCEA G ET AL: "Molecular prognostic markers in pancreatic cancer: A systematic review", EUROPEAN JOURNAL OF CANCER, PERGAMON, vol. 41, no. 15, 1 October 2005 (2005-10-01), pages 2213 - 2236, XP027785527, ISSN: 0959-8049, [retrieved on 20051001] *
IOANNIS A VOUTSADAKIS: "Molecular predictors of gemcitabine response in pancreatic cancer", WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol. 3, no. 11, 1 January 2011 (2011-01-01), pages 153, XP055193080, ISSN: 1948-5204, DOI: 10.4251/wjgo.v3.i11.153 *
JERAN K. STRATFORD ET AL: "A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma", PLOS MEDICINE, vol. 7, no. 7, 1 January 2010 (2010-01-01), pages e1000307, XP055048507, ISSN: 1549-1277, DOI: 10.1371/journal.pmed.1000307 *
PAULA GHANEH ET AL: "Topics: Pancreatic cancer - New horizons in diagnosis and treatment Molecular prognostic markers in pancreatic cancer", J HEPATOBILIARY PANCREAT SURG, 1 January 2002 (2002-01-01), pages 1 - 11, XP055193078, Retrieved from the Internet <URL:http://rd.springer.com/content/pdf/10.1007/s005340200000.pdf> [retrieved on 20150602] *

Also Published As

Publication number Publication date
WO2016091888A2 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
WO2016091888A3 (en) Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics
CL2022002771A1 (en) Affinity matured and humanized antibodies to fcrh5 and their use (cl divisional 201703195).
WO2014144657A3 (en) Compositions and methods for cancer prognosis
WO2015067969A3 (en) Method, array and use thereof for determining pancreatic cancer
BR112018003308A2 (en) chimeric cytokine receptor
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
EA201892489A1 (en) NUMBER OF TARGETS FOR MULTIPLEX OPTIMIZED AMPLIFICATION WITH NON-CONFORMITY (MOMA)
BR112016021004A2 (en) particle library; unnatural isolated t (tcr) cell receptor; use of a library; a method of obtaining a t-cell receptor that specifically binds to a peptide antigen; nucleic acid; method of constructing a particle library; a method of obtaining a t-cell receptor that specifically binds to a peptide antigen; and particle
WO2017194613A3 (en) Method, array and use thereof
MX363201B (en) Method, array and use for determining the presence of pancreatic cancer.
IN2014CN04154A (en)
WO2018013531A8 (en) Autoantibody biomarkers for the early detection of ovarian cancer
WO2015165779A3 (en) Small ncrnas as biomarkers
AR105618A1 (en) METHODATION OF THE PROMOTER OF THE BINDING TO THE PROGRAMMED DEATH RECEIVER (PD-L1) IN CANCER
MX2019008911A (en) Methods, arrays and uses thereof.
WO2018076024A3 (en) Methods for screening b cell lymphocytes
MX2018009505A (en) Method for determining helicobacter pylori.
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
BR112017003895B8 (en) SAMPLE TESTING APPARATUS
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
AU2011263533A8 (en) Method,array and use thereof
ES2684758T3 (en) Procedure to diagnose liver fibrosis
WO2014145467A3 (en) Multiplexed digital assay for variant and normal forms of a gene of interest

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15807863

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15807863

Country of ref document: EP

Kind code of ref document: A2